JP2015522659A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522659A5
JP2015522659A5 JP2015524292A JP2015524292A JP2015522659A5 JP 2015522659 A5 JP2015522659 A5 JP 2015522659A5 JP 2015524292 A JP2015524292 A JP 2015524292A JP 2015524292 A JP2015524292 A JP 2015524292A JP 2015522659 A5 JP2015522659 A5 JP 2015522659A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
analgesics
acetaminophen
naproxen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015524292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522659A (ja
Filing date
Publication date
Priority claimed from US13/560,665 external-priority patent/US8445011B2/en
Priority claimed from US13/800,761 external-priority patent/US20130196012A1/en
Priority claimed from US13/847,940 external-priority patent/US8703184B2/en
Application filed filed Critical
Priority claimed from PCT/US2013/048627 external-priority patent/WO2014018223A1/en
Publication of JP2015522659A publication Critical patent/JP2015522659A/ja
Publication of JP2015522659A5 publication Critical patent/JP2015522659A5/ja
Pending legal-status Critical Current

Links

JP2015524292A 2012-07-27 2013-06-28 夜尿症のための医薬製剤およびその使用の方法 Pending JP2015522659A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13/560,665 US8445011B2 (en) 2010-07-08 2012-07-27 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/560,665 2012-07-27
US13/800,761 2013-03-13
US13/800,761 US20130196012A1 (en) 2010-11-30 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/847,940 US8703184B2 (en) 2010-07-08 2013-03-20 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/847,940 2013-03-20
PCT/US2013/048627 WO2014018223A1 (en) 2012-07-27 2013-06-28 Pharmaceutical formulation for bedwetting and method of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018078173A Division JP2018127482A (ja) 2012-07-27 2018-04-16 夜尿症のための医薬製剤およびその使用の方法

Publications (2)

Publication Number Publication Date
JP2015522659A JP2015522659A (ja) 2015-08-06
JP2015522659A5 true JP2015522659A5 (OSRAM) 2016-07-28

Family

ID=49997724

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015524291A Pending JP2015522658A (ja) 2012-07-27 2013-06-28 排尿頻度を減少させるための医薬製剤およびその使用の方法
JP2015524292A Pending JP2015522659A (ja) 2012-07-27 2013-06-28 夜尿症のための医薬製剤およびその使用の方法
JP2017204851A Pending JP2018039831A (ja) 2012-07-27 2017-10-24 排尿頻度を減少させるための医薬製剤およびその使用の方法
JP2018078173A Pending JP2018127482A (ja) 2012-07-27 2018-04-16 夜尿症のための医薬製剤およびその使用の方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015524291A Pending JP2015522658A (ja) 2012-07-27 2013-06-28 排尿頻度を減少させるための医薬製剤およびその使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017204851A Pending JP2018039831A (ja) 2012-07-27 2017-10-24 排尿頻度を減少させるための医薬製剤およびその使用の方法
JP2018078173A Pending JP2018127482A (ja) 2012-07-27 2018-04-16 夜尿症のための医薬製剤およびその使用の方法

Country Status (16)

Country Link
US (3) US20160022615A1 (OSRAM)
EP (3) EP2877179A4 (OSRAM)
JP (4) JP2015522658A (OSRAM)
KR (2) KR20150048740A (OSRAM)
CN (4) CN107661326A (OSRAM)
AU (3) AU2013293489B2 (OSRAM)
BR (2) BR112015001627A2 (OSRAM)
CA (2) CA2875818A1 (OSRAM)
HK (4) HK1205931A1 (OSRAM)
IL (3) IL236028A0 (OSRAM)
MX (2) MX2015001188A (OSRAM)
MY (1) MY171526A (OSRAM)
RU (3) RU2019101864A (OSRAM)
SG (2) SG11201500578VA (OSRAM)
WO (2) WO2014018222A1 (OSRAM)
ZA (2) ZA201408993B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016317092A1 (en) * 2015-09-01 2018-04-26 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
WO2017058428A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
SG11201805527QA (en) * 2015-09-30 2018-07-30 Wellesley Pharmaceuticals Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
MX2019004191A (es) * 2017-11-07 2020-02-12 Poviva Tea Llc Composiciones de alimentos y bebidas que comprenden inhibidores de pde5.
IL303767A (en) 2021-02-23 2023-08-01 Otsuka Pharma Co Ltd Pharmaceutical formulations of centrapadin, and methods for its preparation and use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE306250T1 (de) * 1998-12-23 2005-10-15 Alza Corp Dosierungsformen, die poröse partikel enthalten
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
BR0113644A (pt) * 2000-08-30 2003-07-29 Lilly Icos Llc Usos do inibidor de pde5 no tratamento de enxaqueca
WO2003029199A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Benzene derivatives, process for preparing the same and use thereof
WO2003070233A1 (en) * 2002-02-19 2003-08-28 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
US7754767B2 (en) * 2002-11-06 2010-07-13 Trinity Laboratories, Inc. Method for treatment of premature ejaculation in humans
US20080009538A1 (en) * 2005-03-21 2008-01-10 Phil Skolnick Methods and compositions for the treatment of urinary incontinence
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
US8399410B2 (en) * 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
CN101664555A (zh) * 2008-09-02 2010-03-10 许洁 用于治疗泌尿生殖系统感染性疾病的联合药物组合物
CN102028693A (zh) * 2009-09-30 2011-04-27 梁超峰 含有5-型磷酸二酯酶抑制剂的直肠给药组合物
US9260424B2 (en) * 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120141554A1 (en) * 2010-07-08 2012-06-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US8236857B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236856B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Similar Documents

Publication Publication Date Title
JP2015522659A5 (OSRAM)
JP2015503583A5 (OSRAM)
JP2015522658A5 (OSRAM)
JP2015510928A5 (OSRAM)
JP2012505884A5 (OSRAM)
JP2015078230A5 (OSRAM)
JP2014507446A5 (OSRAM)
JP2013518107A5 (OSRAM)
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
JP2014218522A5 (OSRAM)
JP2012515184A5 (OSRAM)
JP2013507408A5 (OSRAM)
RU2014131238A (ru) Состав с отсроченным высвобождением для уменьшения частоты мочеиспускания и способ его применения
TN2011000307A1 (en) Galenic formulation of organic compounds
NZ714662A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
RU2015106672A (ru) Фармацевтическая композиция для уменьшения частоты мочеиспускания и способ ее применения
JP2012082195A5 (OSRAM)
JP2012533559A5 (OSRAM)
UY29193A1 (es) Nuevas formulaciones de tabletas de liberación modificada para inhibidores de bomba de protón
CR10801A (es) Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine
JP2015508411A5 (OSRAM)
JP2014504636A5 (OSRAM)
JP2011516544A5 (OSRAM)
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.